Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

440 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Emerging treatment options for type 2 diabetes.
Piya MK, Tahrani AA, Barnett AH. Piya MK, et al. Among authors: barnett ah. Br J Clin Pharmacol. 2010 Nov;70(5):631-44. doi: 10.1111/j.1365-2125.2010.03711.x. Br J Clin Pharmacol. 2010. PMID: 20831513 Free PMC article. Review.
SGLT inhibitors in management of diabetes.
Tahrani AA, Barnett AH, Bailey CJ. Tahrani AA, et al. Among authors: barnett ah. Lancet Diabetes Endocrinol. 2013 Oct;1(2):140-51. doi: 10.1016/S2213-8587(13)70050-0. Epub 2013 Aug 13. Lancet Diabetes Endocrinol. 2013. PMID: 24622320 Review.
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.
Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle HJ, Broedl UC; EMPA-REG RENAL trial investigators. Barnett AH, et al. Lancet Diabetes Endocrinol. 2014 May;2(5):369-84. doi: 10.1016/S2213-8587(13)70208-0. Epub 2014 Jan 24. Lancet Diabetes Endocrinol. 2014. PMID: 24795251 Clinical Trial.
Treatment with the dipeptidyl peptidase-4 inhibitor linagliptin or placebo followed by glimepiride in patients with type 2 diabetes with moderate to severe renal impairment: a 52-week, randomized, double-blind clinical trial.
Laakso M, Rosenstock J, Groop PH, Barnett AH, Gallwitz B, Hehnke U, Tamminen I, Patel S, von Eynatten M, Woerle HJ. Laakso M, et al. Among authors: barnett ah. Diabetes Care. 2015 Feb;38(2):e15-7. doi: 10.2337/dc14-1684. Diabetes Care. 2015. PMID: 25614693 Clinical Trial. No abstract available.
Future glucose-lowering drugs for type 2 diabetes.
Bailey CJ, Tahrani AA, Barnett AH. Bailey CJ, et al. Among authors: barnett ah. Lancet Diabetes Endocrinol. 2016 Apr;4(4):350-9. doi: 10.1016/S2213-8587(15)00462-3. Epub 2016 Jan 23. Lancet Diabetes Endocrinol. 2016. PMID: 26809680 Review.
Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, Trautmann ME. Barnett AH, et al. Clin Ther. 2007 Nov;29(11):2333-48. doi: 10.1016/j.clinthera.2007.11.006. Clin Ther. 2007. PMID: 18158075 Clinical Trial.
440 results